Sarepta jumps 48% to $20.51 after FDA lifts Elevidys hold for some patients
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
4 minutes ago
- Yahoo
Hims & Hers Q2 2025: What You Need to Know Ahead of Earnings
Hims & Hers Health (NYSE:HIMS) reports Q2 2025 earnings after U.S. markets close on Monday, August 4. Analysts expect revenue of around $552 million, up 75% YoY, and adjusted EPS near $0.15, roughly up 15% YoY. Despite the volatility, shares are up 154% YTD, pushing the forward P/E to roughly 57. Subscriber growth remains the core engine investors care about. Subscribers increased 38% in Q1, reaching 2.4 million. Weight-loss GLP-1 offerings are a swing factor, but Novo Nordisk (NYSE:NVO) ended its partnership on 23 Jun 2025, citing illegal mass compounding and deceptive marketing, which sent Hims down 30%. Analysts estimate that up to half of Hims' projected weight-loss revenue could be at risk. Investors need clarity on FDA scrutiny, formulary access, and whether compounded semaglutide margins can hold. Marketing spend, revenue per average user, and progress on the ZAVA integration will also be closely watched. Management guides FY25 revenue of $2.32.4 billion and low-teens EBITDA margins. Any uplift to those guides or clean regulatory commentary could keep momentum intact. But with valuation stretched, even a top-line beat may disappoint if churn ticks up or compliance costs bite. Q2 will test whether the telehealth disrupter can scale responsibly before regulators step in. This article first appeared on GuruFocus. Sign in to access your portfolio
Associated Press
4 minutes ago
- Associated Press
2 Day Pharmaceutical, Biopharmaceutical, Biologics and Medical Device FDA Inspection Preparedness and Compliance Seminar (ONLINE EVENT: September 3-4, 2025)
DUBLIN--(BUSINESS WIRE)--Aug 4, 2025-- The 'FDA Inspection Preparedness and Compliance' training has been added to offering. This is a practical, hands-on two-day seminar designed to provide pharmaceutical, biopharmaceutical, biologics and medical device professionals with the information and tools they require to prepare for and manage an FDA inspection efficiently, effectively and successfully. Many regulated companies preparing for FDA inspections are not prepared and the outcome can be negative as we see all the time with enforcement actions. This seminar provides the fundamentals and the ground rules on how to prepare for and survive an FDA inspection no matter if you are a Class I, II, III device or a pharmaceutical or biologics manufacturer. This presentation will review and emphasize the do's and don'ts and cardinal rules as to interviewing, how to respond, reviewing documentation, etiquette, use of certain words, body language, responding to questions/requests, etc., and certainly replying to 483's and Warning Letters. The course will go through what typically goes on during an FDA Inspection and will then cover how to prepare for, host and follow up to a regulatory inspection. It will emphasize and focus on the critical and vital elements that you should do or not do during the inspection. Typically, FDA inspections can be highly structured and there are procedures that are to be followed as you prepare for state of readiness. It is important for anyone who might be involved in the inspection to be aware of these procedures, including all employees and personnel to ensure there are no surprises. The course will also provide information for inspections conducted by international agencies as well as non-FDA agencies, including self-inspections for manufacturing and the famous FDA Mock Inspection or Mock Audit. It will explain how to prepare for an inspection, how to handle a scheduled or non-scheduled inspection, what to expect during an inspection and what follow up to expect after an inspection. Who Should Attend: This seminar will provide an overview and in-depth snapshot of the entire process for preparing for and managing and FDA inspection and external regulatory inspections and for those companies who must establish proven and sustainable GXP Compliance Strategies and risk mitigation strategies when responding to a crisis. Employees who will benefit include all levels of management and departmental representatives from key functional areas and those who desire a better understanding or a 'refresh' overview of the FDA inspection process from preparing for the inspections, during the inspections and post-inspection responsibilities and follow up activities with FDA, including: This live training Seminar includes the following for each registered attendee: Key Topics Covered: Day 1 Day 2 Recap of Day 1 and Day 2 Exercise on Day 2 Debrief/Adjourn/Wrap-Up Speakers: Kelly Thomas Vice President Stallergenes Greer Ms. Thomas has over two decades of cGMP hands-on industry experience in both pharmaceutical and medical device manufacturing operations. Her experience covers all Quality Systems; as well as, all areas of validation; including, process/product validation, facilities validation, CSV and 21 CFR Part 11, test method validation, equipment/automated processes and cleaning validation. Utilizing strategic thinking, risk based approaches, and Lean principles, she has demonstrated success in steering and managing complex projects within the pharmaceutical and medical device industries. For more information about this training visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. View source version on CONTACT: Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: EDUCATION MEDICAL DEVICES HEALTH PHARMACEUTICAL TRAINING BIOTECHNOLOGY SOURCE: Research and Markets Copyright Business Wire 2025. PUB: 08/04/2025 08:41 AM/DISC: 08/04/2025 08:41 AM
Associated Press
7 minutes ago
- Associated Press
NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Announces Filing of a Citizen Petition with the US Food and Drug Administration Seeking Removal of Benzethonium Chloride from Ketamine Products
WILMINGTON, Del., Aug. 4, 2025 /PRNewswire/ -- NRx Pharmaceuticals, Inc. (Nasdaq:NRXP), a clinical-stage biopharmaceutical company, today announced the filing of a Citizen Petition with the US Food and Drug Administration (FDA), seeking the removal of Benzethonium Chloride from all forms of ketamine sold in the United States. Benzethonium Chloride (BZT) is a preservative with known toxicity that is not Generally Recognized as Safe (GRAS) by the FDA for parenteral products and not Generally Recognized as Safe and Effective (GRASE) for topical products. It belongs to a class of quaternary amine preservatives that is known to be toxic to epithelial cells and to demonstrate neurotoxicity. This class of preservatives has been removed from many eyedrops because of demonstrated toxicity to the conjunctiva and corneal nerves. The FDA no longer allows BZT to be used in hand cleansers and topical antiseptics.1 In June 2025 NRx filed an Abbreviated New Drug Application with the FDA for a preservative-free preparation of ketamine, demonstrating support for 3 year room temperature stability and sterility. NRx has similarly filed a patent on its preservative-free process, in light of prior art that suggested BZT was required for long term stability and sterility. The Company has instituted US-based high volume manufacture, while it awaits generic approval. The Company is additionally seeking a labeled indication for the use of ketamine to treat suicidal depression through the recently-announced FDA Commissioner's National Priority Voucher Program. 'At its introduction in the 1970s, ketamine was developed as an anesthetic and was never intended to be administered repeatedly to patients,' said Dr. Jonathan Javitt, CEO of NRx Pharmaceuticals. 'Ketamine is now widely used on a repeated basis as the only currently marketed drug that has shown benefit in treating suicidal depression and PTSD, although this is currently not a labeled indication. Hence, patients who receive intravenous ketamine on a repeated basis are exposed to a known toxic preservative that cannot be used today in hand cleaner, antiseptics, and other topical products. The European Medicines Agency has warned against its use.2 We believe that our Citizen Petition aligns with priorities articulated by current leadership of the US Department of Health and Human Services to remove potentially toxic additives and preservatives from the US Food and Drug supply and to re-shore the US Drug Supply.' About NRx Pharmaceuticals, Inc. NRx Pharmaceuticals is a clinical-stage biopharmaceutical company developing therapeutics based on its NMDA platform for the treatment of central nervous system disorders, specifically suicidal bipolar depression, chronic pain, and PTSD. The Company is developing NRX-101, an FDA-designated investigational Breakthrough Therapy for suicidal treatment-resistant bipolar depression. NRx plans to file an NDA for Accelerated Approval for NRX-101 in patients with bipolar depression and suicidality or akathisia. NRx has recently filed an Abbreviated New Drug Application (ANDA) for preservative-free ketamine and initiated a New Drug Application filing for NRX-100 (IV ketamine) under the Commissioner's National Priority Voucher Program for the treatment of suicidal depression. The filing is based on results of well-controlled clinical trials conducted under the auspices of the US National Institutes of Health and newly obtained data from French health authorities, licensed under a data sharing agreement. NRx was awarded Fast Track Designation for development of ketamine (NRX-100) by the US FDA as part of a protocol to treat patients with acute suicidality. Notice Regarding Forward-Looking Statements The information contained herein includes forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as 'may,' 'will,' 'should,' 'would,' 'expect,' 'plan,' 'believe,' 'intend,' 'look forward,' and other similar expressions among others. These statements relate to future events or to the Company's future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company's actual results to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. You should not place undue reliance on forward-looking statements since they involve known and unknown risks, uncertainties and other factors which are, in some cases, beyond the Company's control and which could, and likely will, materially affect actual results, levels of activity, performance or achievements. Any forward-looking statement reflects the Company's current views with respect to future events and is subject to these and other risks, including uncertainties and assumptions relating to the Company's operations, results of operations, growth strategy, and, among other things, liquidity. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's most recent Annual Report on Form 10-K and other filings with the Securities and Exchange Commission. Investors and security holders are urged to read these documents free of charge on the SEC's website at Except as may be required by applicable law, the Company assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, whether as a result of new information, future events or otherwise. For further information: 1 U.S. Food and Drug Administration. Final Rule: Safety and Effectiveness of Consumer Antiseptic Wash Products. 81 FR 61106. September 6, 2016. 2 European Medicines Agency (EMA). (2020). Questions and answers on benzalkonium chloride used as an excipient in medicinal products for human use [PDF]. EMA. View original content to download multimedia: SOURCE NRx Pharmaceuticals, Inc.
